日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Implementing generative artificial intelligence in precision oncology: safety, governance, and significance

在精准肿瘤学中应用生成式人工智能:安全性、治理和意义

Hamamoto, Ryuji; Koyama, Takafumi; Takahashi, Satoshi; Yasuda, Tomohiro; Kobayashi, Kazuma; Akagi, Yu; Kouno, Nobuji; Sudo, Kazuki; Hirata, Makoto; Sunami, Kuniko; Kubo, Takashi; Katayama, Hiroshi; Takashima, Atsuo; Taniguchi, Tomonori; Matsumoto, Hiromi; Shibaki, Ryota; Asada, Ken; Komatsu, Masaaki; Kaneko, Syuzo; Yamada, Masayoshi; Horinouchi, Hidehito; Tanaka, Katsuya; Goto, Yasushi; Kato, Ken; Saito, Yutaka; Nakamura, Kenichi; Yamamoto, Noboru

Phase 1 study of rogocekib in patients with relapsed or refractory hematologic malignancies

罗戈塞克治疗复发或难治性血液系统恶性肿瘤患者的1期研究

Yokoyama, Hisayuki; Fukuhara, Noriko; Ando, Koji; Iida, Hiroatsu; Yamauchi, Takahiro; Fukuhara, Suguru; Izutsu, Koji; Tanoue, Yasushi; Yamamoto, Maki; Tozaki, Hirokazu; Takahara, Eiji; Shoji, Shingo; Mizutani, Akio; Morishita, Daisuke; Oda, Robert; Miyake, Hiroshi; Yamamoto, Noboru

Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer

加索拉西布治疗KRAS G12C突变晚期胰腺癌患者的疗效和安全性

Yamamoto, Noboru; Yan, Dong; Ganju, Vinod; Hou, Xinfang; Pan, Hongming; Shan, Jianzhen; Wang, Liwei; Kim, Sang-We; Richardson, Gary; Sanborn, Rachel E; Zhang, Jingdong; Xiang, Ziyong; Wang, Wenjia; Shi, Zhe; Zhang, Ling; Wang, Yaolin; Xu, Rui-Hua

Early Mycophenolate Mofetil Combination Therapy as an Effective Approach for Immune-Related Hepatitis Induced by Immune Checkpoint Inhibitors in Patients With Solid Tumor

早期吗替麦考酚酯联合治疗是治疗实体瘤患者免疫检查点抑制剂诱发的免疫相关性肝炎的有效方法

Igawa, Yukiko Shimoda; Yoshida, Tatsuya; Sato, Jun; Yoshinami, Yuri; Hibino, Yukiko; Arima, Takamichi; Maruki, Yuta; Shoji, Hirokazu; Namikawa, Kenjiro; Sudo, Kazuki; Honma, Yoshitaka; Okita, Natsuko; Hashimoto, Hironobu; Yamazaki, Naoya; Okusaka, Takuji; Yonemori, Kan; Yamamoto, Noboru; Ohe, Yuichiro; Kato, Ken

Pooled safety analysis of pimitespib for the treatment of patients with advanced gastrointestinal stromal tumors

皮米替司匹布治疗晚期胃肠道间质瘤患者的汇总安全性分析

Kurokawa, Yukinori; Yamamoto, Noboru; Hirano, Yuko; Arimura, Naoki; Sun, Chunlan; Doi, Toshihiko

Drug-drug interactions with pioglitazone, losartan, and midazolam and anti-tumor efficacy and safety study of TAS-115 in patients with solid tumors

吡格列酮、氯沙坦和咪达唑仑的药物相互作用以及TAS-115在实体瘤患者中的抗肿瘤疗效和安全性研究

Katsuya, Yuki; Takenaka, Satoshi; Takahashi, Shunji; Yamamoto, Noboru

HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study

HER2选择性酪氨酸激酶抑制剂Zongertinib(BI 1810631)治疗HER2改变的晚期/转移性实体瘤患者:一项Ia期剂量递增研究

Heymach, John V; Opdam, Frans; Barve, Minal; Tu, Hai-Yan; Wu, Yi-Long; Berz, David; Schröter, Lukas; Botilde, Yanick; Sadrolhefazi, Behbood; Serra, Josep; Yoh, Kiyotaka; Yamamoto, Noboru

PD-L1 phenotype classification based on expression in tumor and immune cells as a potential biomarker for optimizing anti-PD-1/CTLA-4 immunotherapies in NSCLC.

基于肿瘤细胞和免疫细胞中表达的 PD-L1 表型分类作为优化 NSCLC 中抗 PD-1/CTLA-4 免疫疗法的潜在生物标志物。

Miyakoshi Jun, Yoshida Tatsuya, Uehara Yuji, Takeyasu Yuki, Shirasawa Masayuki, Fukuda Akito, Kashima Jumpei, Kumagai Shogo, Horinouchi Hidehito, Ono Hanako, Shiraishi Kouya, Kohno Takashi, Kondo Shunsuke, Goto Yasushi, Yamamoto Noboru, Yatabe Yasushi, Hosomi Yukio, Kurata Takayasu, Naoki Katsuhiko, Suzuki Takuji, Ohe Yuichiro

The triad interaction of ULK1, ATG13, and FIP200 is required for ULK complex formation and autophagy

ULK1、ATG13 和 FIP200 三者之间的相互作用是 ULK 复合物形成和自噬所必需的。

Yutaro Hama,Yuko Fujioka,Hayashi Yamamoto,Noboru Mizushima,Nobuo N Noda

A Phase I, First-In-Human Study of CBA-1205, an Anti-DLK1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

一项针对晚期实体瘤患者的抗DLK1单克隆抗体CBA-1205的I期首次人体研究

Katsuya, Yuki; Ikeda, Masafumi; Koyama, Takafumi; Sato, Jun; Okada, Mao; Matsubara, Nobuaki; Kondoh, Chihiro; Mukohara, Toru; Watanabe, Kazuo; Kotani, Daisuke; Ogawa, Yoshimi; Taoka, Shose; Yamamoto, Noboru